{"id":"NCT01059630","sponsor":"Genentech, Inc.","briefTitle":"A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)","officialTitle":"An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04-30","primaryCompletion":"2014-09-30","completion":"2018-11-30","firstPosted":"2010-02-01","resultsPosted":"2016-11-17","lastUpdate":"2020-01-13"},"enrollment":413,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Hodgkin's Lymphoma"],"interventions":[{"type":"DRUG","name":"Obinutuzumab","otherNames":["RO5072759; GA101"]},{"type":"DRUG","name":"Bendamustine","otherNames":[]}],"arms":[{"label":"Bendamustine Alone","type":"ACTIVE_COMPARATOR"},{"label":"Obinutuzumab + Bendamustine","type":"EXPERIMENTAL"}],"summary":"This open-label, multicenter, randomized Phase III study will investigate the efficacy, safety, pharmacokinetics and pharmacoeconomics of obinutuzumab (RO5072759, GA101) combined with bendamustine followed by continued obinutuzumab treatment (maintenance monotherapy) compared with bendamustine alone treatment in participants with rituximab-refractory indolent Non-Hodgkin's lymphoma (iNHL). The end of study was defined to when safety follow-up for all patients had been completed (2 years' safety follow-up from last dose).","primaryOutcome":{"measure":"Number of Participants With Progressive Disease (PD) as Assessed by Independent Review Committee (IRC) or Death","timeFrame":"Baseline until PD or death, whichever occurred first (assessed at baseline, 14 days prior to Cycle [Cy] 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1, then every 3 months up to 2 years and every 6 months for next 2 years [up to 4.5 years overall])","effectByArm":[{"arm":"Bendamustine Alone","deltaMin":125,"sd":null},{"arm":"Obinutuzumab + Bendamustine","deltaMin":87,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":22},"locations":{"siteCount":121,"countries":["United States","Austria","Belgium","Canada","Czechia","France","Germany","Italy","Netherlands","Russia","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["31462735","31050355","29584548","27345636"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":76,"n":203},"commonTop":["INFUSION RELATED REACTION","NAUSEA","FATIGUE","NEUTROPENIA","DIARRHOEA"]}}